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Abstract 
Ovarian cancer is rare in childhood. This explains scattered literature reports and lack of 
specific pediatric treatment. This review gives an overview of the Belgian data from 2004-
2013, as well as insight in the literature. Based on these findings, we propose the following 
strategy to index ovarian masses and malignancies in children better in the future: first of all, 
the improvement of worldwide data collection and second, the use of a reproducible 
definition of childhood, malignancy and ovarian mass.  
Ovarian cancer in children: a rare disease  
The most important childhood cancers are: leukemia, central nervous system tumors and 
neuroblastoma.[1] Tumors of the female genital tract in children and adolescents are rare. 
Amongst them, ovarian cancer is the most frequent one, in total 1% of all childhood 
cancers.[2] According to the SEER database (The Surveillance, Epidemiology and End Results 
of the National Cancer Institute, USA), 1.3% of all ovarian cancers between 2008 and 2012 
were diagnosed in patients below the age of 20. This makes ovarian cancer in children 
extremely rare and therefore hard to study. Benign ovarian masses on the other hand are 
more frequent with approximately 2,6/100 000 girls each year.[3]  
The distribution of pathology in ovarian cancer is different in children compared to adults 
(table 1). Ovarian cancer is the most important gynaecologic cancer in children, but a far 
second in adult women.[4] Epithelial ovarian carcinomas account for 90% of all ovarian 
cancers in adults. High-grade serous ovarian cancer (HGSOC) is the most frequent subtype. 
Prognosis of HGSOC remains poor. This explains the poor prognosis of ovarian cancer in adults. 
HGSOC metastasizes throughout the abdomen before causing symptoms, resulting in a 
diagnostic delay, leading to a poor prognosis. Nowadays, 80% of adult ovarian cancer patients 
still die. In children however, the most frequent ovarian cancer is non-epithelial.  Most often, 
their ovarian cancers arise from germ cells (GCT). Less than 20% of ovarian cancers in children 
are epithelial in origin, with a predominance of serous and mucinous histology.[6,7] The 
overall prognosis of ovarian cancer in children is excellent compared to adults, because of a 
different histological distribution. [7,8] According to the study of Mangili G et al. reporting the 
largest database on ovarian germ cell, there are two important contributing factors to the 
prognosis of GCT: first, the majority (71%) is detected at stage I and second, they respond well 
to surgery and chemotherapy leading to a 5-year survival of 95.6% and 73.2% in stage I and 
advanced stages, respectively.[9] Because of this excellent prognosis of germ cell tumors, 
overall outcome of ovarian cancer in children is excellent compared to adults. 
 
Literature review 
Table 2 and Figure 1 give an impression of the reported cases of ovarian childhood cancer in 
literature.[8,10–41] It is clear that this only provides us a scattered overview of pediatric 
ovarian neoplasms, which is difficult to interpret. Each center publishes locally available data. 
The number of ovarian childhood cancers in the total amount of ovarian masses (both benign 
and malignant) differs enormously.  On average, this results in a risk of malignancy of adnexal 
masses in children of +/- 19% with a range from 2 to 59%. This is an enormous discrepancy. 
This difference cannot be explained by geographical differences alone. For this we see three 
additional causes: 1/Benign cysts and teratomas are often treated locally and not referred to 
a specialized pediatric oncologist and therefore will remain underreported. Thus artificially 
lowering the total amount of ovarian masses and artificially increasing the proportion of 
cancers, 2/Differences in the study populations used in the case series. Some groups only 
report adnexal masses up to the age of 15, as was done by Del Mar et al. while other groups 
include patients until the age of 19.[8] At this moment, children with cancer up to the age of 
16 years are referred to a pediatric oncology unit, 3/ Terms and definitions used 
to describe ovarian masses differ from paper to paper. The golden standard for the diagnosis 
of an ovarian neoplasm is the ultrasound definition defined by the IOTA (International Ovarian 
Tumor Analysis) criteria: it is the part of an ovary or the total ovary that is not part of the 
normal ovarian physiology. [42]  
Despite differences in reporting, it is clear from the Belgian data as from the literature data 
that there is a positive correlation of ovarian cancer with age (Figure 2).[8,14–32,34–41] 
Moreover, there might even be an underestimation of the incidence in older children, for 
reasons stated above. On the other hand, this finding might partially be explained by an 
increase in ovarian cancers after menarche.   
 
Management of ovarian cancer in children 
* Germ cell tumors, the most common ovarian cancer 
In 2014, the Gynecologic Cancer Intergroup (GCIG) formulated a consensus on ovarian germ 
cell tumors.[43] Since most tumors are unilateral and diagnosed as stage I disease, fertility-
sparing surgery appears to be safe. In case of FIGO stage II disease or higher, surgery has to 
be extended, keeping in mind that the uterus usually can be preserved in case of a bilateral 
tumor. The administration of neoadjuvant chemotherapy, prior to debulking surgery (as is 
accepted in widespread epithelial ovarian cancer in adults [44]) can be considered in children 
with widespread dysgerminomas since the tumor is highly chemosensitive. Standard 
chemotherapy for advanced or incompletely resected GCT is BEP (Bleomycine, Etopiside, 
Cisplatinum q3w), alternatively JEB can be used in young children (Carboplatin replacing 
Cisplatin) or PEI (Cisplatin, Etoposide, Ifosfamide). Consequently, since more than 90% of 
children will survive their disease, the mapping and follow up of the side effects is of utmost 
importance. Most frequent side effects of BEP/JEB/PEI chemotherapy are lung toxicity from 
bleomycine, ototoxicity, neurotoxicity and kidney failure from cisplatin, tubular nefropathy 
from ifosfamide and the risk of acute myeloid leukemia or myelodysplastic syndrome in the 
case of etoposide. In a report from Zhang et al. there were no negative effects on fertility of 
BEP chemotherapy after fertility sparing surgery for GCT.[45,46] Two studies by Matei D et al. 
and Gershenson DM et al. reported no obvious physical adverse long-term events after 
treatment for GCT.[47,48] 
 
*Epithelial ovarian carcinoma: rare and lethal 
This cancer arises most frequently in the age group of 15 – 19 years. In a report by Von Allmen 
et al. is stated that up to 20% of ovarian malignancies in children arise from the surface 
epithelium. In a subgroup of patients, high-grade serous ovarian cancer arises from precursor 
lesions called serous tubal intraepithelial carcinomas (STICs) that reside within the distal, 
fimbrial end of the fallopian tube for up to 5 years before progressing to invasive disease.[49] 
Prognosis for epithelial ovarian cancer in adolescents is better compared to adults, with 60% 
overall survival in the review of Kolwijck et al. describing ten advanced stage serous ovarian 
carcinomas in children[50]. This can be explained by tumor grade. The majority of epithelial 
ovarian cancers in children reported in literature are mucinous ovarian cancers or low-grade 
serous ovarian cancers. This is clearly different from the adult population, where the majority 
has a high-grade serous histology. Nevertheless, both for children and for adults, serous 
ovarian cancer will present most often at stage III or IV, with the typical features of a bloated 
abdomen, dyspnea and abdominal pain. Epithelial ovarian cancer in children is not restricted 
to serous and mucinous carcinoma: Deprest et al. described four clear cell ovarian carcinomas 
and one Brenner tumor and in the literature overview (table 2) an endometrioïd ovarian 
carcinoma [15], two small cell ovarian cancers of the hypercalcemic type [19,38] and several 
sarcomas were reported.[19,30,35] Small cell ovarian carcinoma of the hypercalcemic type is 
a rare entity in ovarian cancer and has a propensity for the younger age group, but is not 
limited to children.[51] In contrast to the balanced and well reported treatment schedule for 
children with GCTs, epithelial ovarian cancer in children is treated as adults with a 
combination of surgery and platin-based chemotherapy.[44] In epithelial ovarian cancer, in 
contrast to pure dysgerminoma, it is however very important that all macroscopic tumor is 
resected. Therefore, fertility sparing surgery will be considered in theory, but will very often 
not be applicable if patients are diagnosed at stage II-IV.[52] However, the knowledge on 
epithelial ovarian cancer in children is scarce since they are only a minority of childhood 
ovarian cancers. Therefore, we believe it would be beneficial if these cases could be referred 
to pediatric gynecologic oncology centers and treated in international study protocols.  
Belgian data  
In Belgium, all cancers are registered in a national database since 2004. 
(www.kankerregister.org) Absolute numbers and incidence rates are available until 2013 for 
all cancers in all age groups. Observed survival rates are calculated for all patients diagnosed 
between 2004 and 2013, with a last follow-up at the 1st of July 2015. 
Ovarian cancer in general is classified according to the ICD-10 classification (International 
Classification of Diseases, 10th version). Ovarian pediatric cancer, including children until the 
age of 19, can be sub classified by using the ICCC-3 (International Classification of Childhood 
Cancer, 3rd edition).[53] These classification systems are not identical. For example, juvenile 
granulosa cell tumors will be categorized differently according to the used classification 
system. The incidence of ovarian cancer in children in the different age groups per year, 
compared to the numbers in adults (ICD-10 classification used) is depicted in table 3.  
Between 2004 and 2013, 63 children and adolescents (0 to 19 years old), developed ovarian 
cancer on a total of 8604 ovarian cancers in Belgium (0,7%). Of them 86% was 10 years or 
older. Table 4 further subclassifies the ovarian tumors in the pediatric population, using the 
ICCC-3 classification.  Our data corresponds with literature that GCT are by far the largest 
group and that epithelial carcinomas are rare. As indicated in Table 1, GCT can be further 
subclassified in different groups, based on the degree of differentiation and the cellular 
components present in the tumor. Figure 3 gives an overview on the distribution of these 
subtypes for the Belgian childhood population. No choriocarcinomas were reported. Of note, 
metastatic lesions to the ovary and juvenile granulosa cell tumors were not registered as 
malignant lesions of the ovary in the Belgian database based on the ICCC-3 classification.  
 
 
Conclusions and recommendations 
As ovarian cancer in children and adolescents remains a rare disease it is important to have a 
good registration and centralization. The majority of these cancers are GCT, which have often 
an excellent prognosis when treated correctly. However, data on epithelial ovarian cancer are 
limited and at this moment, there is no specific pediatric treatment. The existing data in 
literature are often contradictory and therefore not of real use for the clinical practice. To 
ameliorate this, we propose the following strategy:  
1. Population wide data collection. The enormous efforts of the national cancer registers 
are of utmost importance. However, a transnational grouping of these cancers in a 
European or worldwide database will further improve our knowledge of the incidence 
of malignancy, without the bias of patient selection in referral clinics.  
2. Consensus on the definitions to be used: what is an ovarian mass? How will we treat 
and classify tumors in adolescents and young adults? What is malignant and what is 
benign? It will be important not only to report the tumor type (germ cell vs sex cord 
stromal vs epithelial and other) but also to report the specific histopathological sub 
classification. This will be important information to interpret survival curves of 
children with ovarian cancer.  
3. Participation in international clinical trials to determine prognostic factors and risk 
groups for treatment stratification; therapy descalation in low risk groups to improve 
quality of life and reduce long term sequellae. 
Highlights 
- GCT are the most frequent type of ovarian cancer in children and have an excellent 
prognosis 
- Epithelial ovarian cancer in children is very rare and therefore poorly studied. There 
is no specific treatment schedule and prognosis is clearly worse than for germ cell 
tumors 
- Literature data are conflicting due to different classifications used and bias in 
reporting  
- Collection of data nationwide and throughout Europe to improve our knowledge in 
this rare tumor type is recommended. 
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 Figure 1. Age distribution of ovarian cancer cases in children in literature. Absolute numbers are 
shown. [8,10–41] 
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 Figure 2 Distribution of different histological types of ovarian cancer derived from the Belgian data 
(A), literature (B).[8,19–23,30–45,47–52] Germ cell tumors are most frequent in both series, followed 
by epithelial tumors.    
 
 
 
 
 
 
 
 
 
 
 
 
Total=61
GCT (83,6%)
Sex cord stromal tumor (4,9%)
Epithelial tumor (11,4%)
Total=831
GCT (69,2%)
Sex cord stromal tumor (11,4%)
Epithelial tumor (16,5%)
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 Figure 3 Distribution of GCT in Belgium based on the data of 2004-2013.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total=51
Yolk sack tumor (12%)
Malignant teratoma (37%)
Mixed germ cell tumor (14%)
Germinoma (35%)
Emryonal carcinoma (2%)
Table 1 Classification of ovarian tumors according to the WHO classification 
Epithelial 
Serous 
Mucinous 
Endometrioid 
Clear cell 
Transitional cell 
Epithelial-stromal (adenosarcoma, 
carcinosarcoma) 
Non-epithelial 
Germ cell 
Dysgerminoma 
Yolk sac 
Monodermal 
Mixed 
Teratoma 
Sex Cord Stromal 
Granulosa cel tumor 
Sertoli-Leydig 
Mixed 
Metastases 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2 Overview of case series in literature from 1984-2014.  
Author, year 
Number 
of 
children 
with 
adnexal 
masses 
Total number 
of children 
with ovarian 
cancer 
GCT 
Sex cord 
stromal 
tumor 
Epithelial 
tumor 
Other* 
Junaid et al. 
1981 [26] 
73 29 13 9 4 3 
Ehren et al. 
1984 [27] 
63 13 12 / 1 / 
Cronen et al. 
1988 [28] 
30 8 6 1 1 / 
Diamond et al. 
1988 [29] 
137 7 5 / 2 / 
Gribbon et al. 
1992 [30] 
NR 38 29 6 2 1 
Brown et al. 
1993 [19] 
91 22 14 3 4 1 
Van Winter et 
al. 1994 [31] 
521 42 17 9 14 2 
Imai et al. 1994 
[32] 
114 21 14 4 3 / 
Major et al. 
1995 [33] 
NR 16 11 1 3 1 
Piipo et al. 
1999 [21] 
79 7 / 2 5 / 
Freud et al. 
1999 [34] 
34 8 4 3 / 1 
Quint et al. 
1999 [35] 
52 5 1 1 / 3 
Menczer et al. 
1999 [36] 
NR 82 59 2 21 / 
Akyüz et al. 
2000 [37] 
NR 56 52 2 1 1 
Cass et al. 2001 
[38] 
102 9 6 3 / / 
Martelli et al. 
2003 [39] 
290 172 141 9 12 10 
Deligeorgoglou 
et al. 2004 [40] 
44 1 / 1 / / 
Schultz et al. 
2005 [41] 
67 35 25 8 3 / 
Islam et al. 
2008 [42] 
49 8 6 2 / / 
Ryoo et al. 
2009 [43] 
396 58 26 5 26 1 
Del Mar et al. 
2010 [8] 
53 27 21 5 / 1 
Yeap et al. 
2010 [23] 
NR 15 14 / 1 / 
Al Jama et al. 
2011 [44] 
52 7 7 / / / 
Loh et al. 2012 
[45] 
78 11 6 3 2 / 
Khemakhen et 
al. 2012 [46] 
31 1 / 1 / / 
Ammor et al. 
2012 [47] 
18 7 7 / / / 
Spinelli et al. 
2012 [22] 
120 5 3 / 2 / 
Liu et al. 2013 
[49] 
203 30 17 3 10 / 
Mukhopadhyay 
et al. 2013 [48] 
49 33 32 / / 1 
Cribb et al. 
2014 [20] 
219 23 13 4 5 1 
Zhang et al. 
2014 [50] 
521 60 32 8 21 1 
Taskinen et al. 
2015 [51] 
45 13 10 1 1 1 
Peroux et al. 
2015 [52] 
41 16 9 5 2 / 
Total 3572 885 612 101 146 29 
 
NR, not reported; GCT: germ cell tumor 
*includes metastatasis from other tumors such as a localisation of a lymphoma in the ovary 
and gonadoblastomas 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Table 3. Number of cases of ovarian cancer (all histologies) per age group per year for Belgium. 
Classification of malignancy based on ICD-10 (International Classification of Disease) 
Year 0-4 yr 5-9 yr 10-14 yr 15-19 yr All ages 
2004 0 1 0 1 915 
2005 0 0 4 3 924 
2006 0 0 0 6 909 
2007 0 1 5 4 920 
2008 0 1 0 2 876 
2009 1 0 4 0 781 
2010 1 0 1 2 865 
2011 0 1 8 4 828 
2012 0 2 0 7 820 
2013 0 1 2 1 766 
TOTAL 2 (0,02%) 7 (0,08%) 24 (0,28%) 30 (0,35%) 8604 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Table 4. Sub classification of ovarian cancers in children (Belgian Cancer registry (2004 - 2013)) 
 
 
 Total 0-14 yr 15-19 yr 
1 year 
OS (%) 
5 year 
OS (%) 
GCT 51 29 22 100 89.4 
Malignant epithelial 
tumor 
7 0 7 - - 
Malignant sex cord 
stromal tumor 
3 2 1 - - 
GCT: germ cell tumor; OS: overall survival; -: not available 
 
